News Conference News AHA 2025 Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI Todd Neale November 09, 2025
News Conference News AHA 2025 One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients Todd Neale November 08, 2025
News Conference News AHA 2024 ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery Yael L. Maxwell November 17, 2024
News Conference News AHA 2022 Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI Shelley Wood November 10, 2022
News Conference News AHA 2022 RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl Todd Neale November 10, 2022
News Conference News AHA 2022 BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI Shelley Wood November 06, 2022
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2019 Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS Todd Neale November 20, 2019
News Conference News AHA 2018 Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF Todd Neale November 11, 2018
News Conference News AHA 2017 RE-DUAL PCI Findings Consistent Across Key Subgroups Todd Neale November 16, 2017
News Conference News AHA 2017 DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy Yael L. Maxwell November 12, 2017
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
News Conference News AHA 2015 Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants Yael L. Maxwell November 10, 2015
News Conference News AHA 2012 Evidence Continues to Support Dabigatran Treatment in A-fib November 06, 2012
News Conference News ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients November 13, 2011